Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 79.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,542 shares of the company's stock after acquiring an additional 47,528 shares during the period. Barclays PLC owned approximately 0.27% of Keros Therapeutics worth $1,703,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KROS. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the 4th quarter valued at about $388,000. Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics in the fourth quarter valued at approximately $99,000. China Universal Asset Management Co. Ltd. lifted its stake in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after acquiring an additional 1,372 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its holdings in Keros Therapeutics by 1,910.2% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 74,255 shares of the company's stock worth $1,175,000 after acquiring an additional 70,561 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

KROS stock opened at $14.65 on Friday. The company has a market cap of $594.95 million, a price-to-earnings ratio of -2.81 and a beta of 1.39. The company has a fifty day moving average price of $11.92 and a 200 day moving average price of $26.32. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analysts Set New Price Targets

KROS has been the subject of several recent analyst reports. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Wells Fargo & Company decreased their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Piper Sandler dropped their price objective on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a report on Friday, January 17th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Finally, Truist Financial lowered their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $40.33.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.90% of the company's stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.